EUVIMEDEUVIMED entdecken
Vergleichsstudie

Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study

Yuwen Zhou, Qian Xu, Jialing Wang, Wei-Bing Leng, Peng Cao, Ye Chen, De-Yun Luo, Meng Qiu iD, Jiyan Liu

Journal of Evidence-Based Medicine · 2024

DOI: 10.1111/jebm.12652 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Evidence-Based Medicine, 2024. Verfasst von Yuwen Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Bevacizumab, Propensity Score, Quinazolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: The Department of Science and Technology of Sichuan Province, The Postdoctor Research Fund of West China Hospital, Sichuan University, The Nation-Sponsored Postdoctor Researcher Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to compare the effectiveness and safety of the combination of raltitrexed, S‐1 (RS), and fruquintinib with the combination of RS and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).

Methods

This retrospective cohort included mCRC patients who received the RS plus fruquintinib or regorafenib as the third‐line therapy from May 2019 to April 2023. A propensity score matching (PSM) analysis was used to balance the baseline characteristics of all patients. Overall survival (OS), progression‐free survival (PFS), tumor response, and safety of the two regimens were evaluated.

Results

Of the 153 patients enrolled, 123 patients received the RS plus bevacizumab and 30 patients received the RS plus fruquintinib. After PSM, 30 pairs were analyzed. Patients treated with RS plus fruquintinib had a longer PFS than those treated with RS plus bevacizumab before PSM (5.0 months vs. 4.3 months, p = 0.008) and after PSM (5.0 months vs. 4.4 months, p = 0.012). A longer OS was also observed in RS plus fruquintinib group before PSM and after PSM, but there was no statistic difference between two groups after PSM. Both objective response rate and disease control rate were higher in the RS plus fruquintinib cohort than those in the RS plus bevacizumab cohort before PSM, and the difference in values between the two groups reduced after PSM. The adverse effects (AEs) of both groups were well tolerated.

Conclusion

In patients with refractory mCRC, RS plus fruquintinib demonstrated a superior OS, PFS than RS plus bevacizumab and had manageable AEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBevacizumabPropensity ScoreQuinazolinesAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsTegafurHumansMaleFemaleRetrospective StudiesMiddle AgedAgedOxonic AcidBenzofuransAdultProgression-Free SurvivalThiophenes

Stichwörter der Autor:innen

S‐1bevacizumabcolorectal cancerfruquintinibprognosisraltitrexed

Substanzen

BevacizumabQuinazolinesDrug CombinationsTegafurraltitrexedOxonic AcidS 1 (combination)HMPL-013BenzofuransThiophenes

Autor:innen und Institutionen

  • Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • West China Medical Publishers, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Biotherapy, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Abdominal Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.

ORCID-Profile: Meng Qiu

Förderung

  • The Department of Science and Technology of Sichuan Province
  • The Postdoctor Research Fund of West China Hospital, Sichuan University
  • The Nation-Sponsored Postdoctor Researcher Program
  • The 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University

Zitieren

APA

Zhou, Y., Xu, Q., Wang, J., Leng, W. B., Cao, P., Chen, Y., Luo, D. Y., Qiu, M., & Liu, J. (2024). Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study. Journal of Evidence-Based Medicine. https://doi.org/10.1111/jebm.12652

Vancouver

Zhou Y, Xu Q, Wang J, Leng WB, Cao P, Chen Y, et al. Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study. Journal of Evidence-Based Medicine. 2024. doi:10.1111/jebm.12652

BibTeX
@article{Zhou2024,
  author = {Zhou, Yuwen and Xu, Qian and Wang, Jialing and Leng, Wei-Bing and Cao, Peng and Chen, Ye and Luo, De-Yun and Qiu, Meng and Liu, Jiyan},
  title = {Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study},
  journal = {Journal of Evidence-Based Medicine},
  year = {2024},
  doi = {10.1111/jebm.12652}
}
Kostenlos starten →